Neurolymphomatosis …

Peripheral Neuropathies

Updated 08.12.2024
Released 01.22.2002
Expires For CME 08.12.2027

Neurolymphomatosis

Authors: Florian P Thomas MD MA PhD MS, Niranjan N Singh MD

See Contributor Disclosures

Editor: Louis H Weimer MD

Neurolymphomatosis

In This Article

Quick Link

Introduction

Historical note and terminology

The term neurolymphomatosis is used to describe peripheral nervous system or spinal root disease resulting from infiltration by malignant lymphoma cells (15; 31). This phenomenon was originally recognized by Marek, who observed a neuropathy in four chickens and found demyelination and lymphomatous nerve infiltrates with sparing of internal organs in one autopsy (47). Now referred to as Marek disease, it is recognized as a T-cell lymphoma in fowl associated with a Herpes virus (43). Pappenheimer and colleagues attempted to reproduce this condition in experimental chickens in order to identify its etiology; they coined the term “neurolymphomatosis gallinarum” (54). Association with leukemia was described in a report of a young man who died 1 month after presenting with sensorimotor polyneuropathy, anemia, and splenomegaly; autopsy showed leukemic involvement of nerves, liver, kidney, and spleen (27). The term "peripheral lymphomatosis" was proposed by Lhermitte and Trelles for the case of 67-year-old woman with malignant neuropathy and lymphoid nerve infiltrates but no systemic or brain involvement (44).

A histologically similar case of multiple relapsing-progressive mononeuropathies was described by Garcin and colleagues (20). They report that an autopsy 7 months after onset demonstrated generalized nerve enlargement and diffuse lymphomatous infiltration of essentially all nerves, dural spaces, and central nervous system with sparing of internal organs. Radnai and Takacs Nagy described a 36-year-old woman with multiple mononeuropathies and lymphomatous involvement of the brain and peripheral nervous system but not the spinal cord, and of internal organs but not lymphoid organs (58).

Allison and Gordon used the term "reticulosis of nervous system" for the case of a 56-year-old woman with progressive sensorimotor peripheral and cranial neuropathies, characterized by lymphomatous nerve infiltrates (03). Barron and colleagues described a case associated with Hodgkin disease (07). Gherardi and colleagues presented two patients with T cell lymphomatous infiltrates (21). Diaz-Arrastia and colleagues presented a literature review dedicated to neurolymphomatosis (15). Vital and colleagues detected retrovirus-like particles consistent with HTLV-1 on electron microscopy of peripheral nerves with T-cell lymphomatous infiltrates (78). Abad and colleagues described four cases of neurolymphomatosis with malignant infiltration in Waldenstrom macroglobulinemia (01).

Clinical manifestations

Presentation and course

Peripheral neurolymphomatosis is a rare neurologic manifestation of non-Hodgkin lymphoma in which peripheral nerve infiltration of lymphoma cells is a dominant feature both clinically and pathologically. It can be difficult to distinguish from leptomeningeal lymphoma (32), as these patients can present with signs and symptoms attributable to involvement of the peripheral nerves, which include radicular pain, cranial nerve deficits, lower motor neuron disease, or cauda equina syndrome (06).

The International Primary CNS Lymphoma Collaborative Group retrospectively analyzed 50 patients over a 16-year period (26). Neurolymphomatosis was related to non-Hodgkin lymphoma in 90% and to acute leukemia in 10%. It was the initial manifestation of malignancy in 26% of cases. Affected neural structures included peripheral nerves (60%), spinal nerve roots (48%), cranial nerves (46%), and plexus (40%), with multiple site involvement in 58%. Neurolymphomatosis was also reported as a relapse of intravascular large B cell lymphoma (48).

When peripheral nerves are primarily involved, a variety of neurologic syndromes occurs. The most common syndrome is a progressive sensorimotor polyneuropathy (70; 15). These patients typically present with asymmetric painful neuropathy or paresthesias of the distal extremities with progression to weakness of the proximal or distal extremities over weeks to months. They can develop hyporeflexia, fasciculations, lancinating pain, or diminished cutaneous sensation in a stocking and glove distribution. In addition to polyneuropathy, mononeuropathies occur; these include sciatic neuropathy (80), median neuropathy (36), radial neuropathy (67), and peroneal neuropathy (23). Other syndromes described are mononeuritis multiplex (79), including multiple cranial neuropathies (37), cauda equina syndrome (Abuzinadah and Almalik 2012), plexopathy (56; 52), polyradiculopathy (75), complex regional pain syndrome (39), pseudodiabetic syndrome (ataxia, areflexia, and Argyll-Robertson pupils) due do infiltration of the ciliary nerves and ganglion (42), or nerve root involvement (51).

Aside from the typical course, fulminant courses have been described that resemble acute inflammatory demyelinating polyneuropathy (63; 72; 11). There was one case of relapsing-remitting polyneuropathy; exacerbations were associated with infections, fatigue, or surgical procedures (09).

Prognosis and complications

The prognosis of neurolymphomatosis is difficult to separate from that of the underlying malignancy. In an International Primary CNS Lymphoma Collaborative Group report, response to treatment was observed in 46% (26). Median overall survival was 10 months, with 12- and 36-month survival rates of 46% and 24%, respectively. Patients will relapse solely with neurolymphomatosis, despite ongoing complete remission at sites outside the nervous system. Prognosis of these patients is poor.

Excluding neurolymphomatosis, the cure rate for Hodgkin disease stages IA and IIA after radiation therapy is 90% and 70%, respectively. Patients with low-grade non-Hodgkin lymphoma live an average of 10 years after diagnosis, until the malignancy transforms to higher grade. Of those with high-grade non-Hodgkin lymphoma, only 35% are disease-free at 5 years; patients with disease relapses have a worse prognosis, with a 5-year survival of less than 10% (46). Diaz-Arrastia and colleagues found that 36 out of 40 patients had their outcome described (15). They were followed for 3 months to 7 years, with a 75% mortality rate. There was occasional improvement with prednisone, chemotherapy, radiation, or surgery. Instances of systemic spread of lymphoma in patients with solitary peripheral neurolymphomatosis as late as 3 years after treatment emphasize the need for close follow-up (57).

Clinical vignette

A 79-year-old woman was in good health until 1 year prior to admission, when she developed numbness and tingling in both feet and later in the hands (70). In the 6 months before admission she lost 12 pounds of weight, developed difficulty walking, and fell frequently because of unsteadiness and pain in the soles of her feet. She admitted to moderate alcohol abuse over several years. On examination she had mild lymphadenopathy. Muscle power was generally reduced to 4/5 (British Medical Research Council Classification); knee and ankle reflexes were absent; and plantars were flexor. There was panmodal sensory loss in the legs and a wide based, ataxic gait; a Romberg sign was present. The patient ambulated with a walker. Laboratory data were remarkable for a white blood cell count of 31,000, a hematocrit of 45, and a platelet count of 270,000. Serum protein electrophoresis, quantitative immunoglobulins, folate, and B12 levels were all normal. Cerebrospinal fluid analysis showed a lymphocytic pleocytosis without atypical cells. Glucose was 63 mg/100 ml, total protein was 32 mg/100 ml, and oligoclonal bands were absent. EMG and nerve conduction studies revealed a demyelinating neuropathy with sensorimotor involvement. Motor nerve conduction velocities were reduced: left median 36.3 m/s (normal 49), left ulnar 33.3 m/s (normal 48), left peroneal 25 m/s (normal 44), and left posterior tibial 23 m/s (normal 43). Sensory nerve conduction velocities were also reduced: left median 35.4 m/s (normal 54) and left sural 35 m/s (normal 43). The response after proximal stimulation of the posterior tibial nerve was 30% of the amplitude of the distal response consistent with a 70% conduction block. There was no denervation. A myelogram was noncontributory. Cell marker analysis of peripheral blood lymphocytes revealed a monoclonal B cell population with CD20+, CD5- lymphocytes that expressed HLA-DR and moderately high-density surface immunoglobulins of the gamma-IgM and gamma-IgD isotypes. Light microscopy of a sural nerve biopsy showed moderate reduction of myelinated fibers and a moderate number of myelin ovoids.

Sural nerve biopsy

(A) Semithin section of sural nerve showing moderate reduction in the number of myelinated fibers. (B) Hematoxylin and eosin-stained paraffin section of sural nerve showing myelin ovoids (arrows) and monomorphic lymphoid cell infi...

The epineurium showed several perivascular foci of monomorphic small lymphoid cells. Scattered small lymphoid cells were located in the endoneurium of one fascicle. The lymphoid cells in the epineurium were CD22+ and CD5-. No CD22+ cells were encountered in the endoneurium. The hematopathologic and immunophenotypic findings were consistent with a small lymphocytic lymphoma. Treatment began with prednisone 50 mg orally per day for 5 days and cyclophosphamide 1 g intravenously every 3 weeks. She was then maintained on chlorambucil 2 to 4 mg orally per day. She stopped drinking alcohol. Although her white cell count normalized, the neuropathy did not improve but progressed slowly for 6 months. In this case, the chronic neuropathy was the presenting feature leading to the diagnosis of a lymphoproliferative disorder characterized by CD5- B cells. Even though the nerve conduction study documented segmental demyelination, the neuropathological findings were consistent with axonal degeneration, as the segmental demyelination was not included in the tissue sampled for biopsy.

Biological basis

Etiology and pathogenesis

Malignant lymphomas are divided into non-Hodgkin lymphoma and Hodgkin disease. Non-Hodgkin lymphoma is subdivided into B-cell and T-cell types, with B-cell types comprising approximately 90% of the cases. In a review by Diaz-Arrastia and colleagues, 39 of 40 patients had non-Hodgkin lymphoma, and the other had Hodgkin disease. Among the non-Hodgkin lymphoma cases, nine were B-cell types (15). Isotypes include IgM, IgA combined IgM and IgD, and both kappa and lambda light chains (29; 71; 70; 15; 24; 01; 40; 52).

Diaz-Arrastia and colleagues suggested that the neuropathy and lymphoma may be caused by a virus with neurotropic properties (15). Kuroda and colleagues presented the case of a HTLV-1 seropositive patient with T-cell neurolymphomatosis (41). Vital and colleagues described retrovirus-like particles in lymphomatous T cells infiltrating nerves (78). Polymerase chain reaction analysis detected sequences resembling the HTLV-1 Tax gene, suggesting that the lymphoma was caused by HTLV-1. In analogy to Marek disease (43), other viruses have been considered. Pietrangeli presented a patient who had negative polymerase chain reaction studies for Epstein-Barr virus and human Herpes virus type 8 (56).

The exact mechanism of how the malignant cells penetrate the peripheral nervous system has yet to be understood. Possible mechanisms are direct neuronal invasion after binding to vascular cell adhesion molecules (35), hematogenous metastasis, or penetration of the CSF space along spinal roots (50). In addition, extranodal lymphoma restricted to the peripheral nervous system may spread systemically (57; 29; 18; 68; 51). Solitary extranodal lymphoma may result from malignant transformation of cells located in intraneural lymphatic channels (50).

Much like the brain, which has a blood-brain barrier to limit access of many compounds into the central nervous system, the peripheral nervous system has a blood-nerve barrier composed of tight capillary endothelial junctions, which accounts for relative resistance to hematogenous spread of tumoral cells (50). Zimmermann reviewed the pathology of 7000 cases of lymphomas involving neural structures and found 10 with peripheral nerve involvement (81). All had extension of malignant cells along blood vessels or invasion between myelin sheaths resulting in destruction of myelin sheaths and axons. A hematogenous mechanism is supported by perineurial location of large atypical lymphoid cells in the perivascular space leading into the nerve bundle (57; 04); however, this is not always present (63; 70; 65; 15; 24), which naturally may represent sampling bias.

Lymphomatous cells may bypass the blood-nerve barrier via several mechanisms. They can access the peripheral nervous system through direct penetration from the leptomeninges, dorsal root ganglia, or spinal roots (where the blood nerve barriers is less tight) traveling in the CSF space along nerve fibers (15; 50), or they can bind to cell adhesion molecules on peripheral nerves. Neural cell adhesion molecules contain homophilic properties found in variable amounts in the brain, meninges, peripheral nervous system, muscle, and certain CD56+ T-cell lymphoma cells, suggesting that these T cells may be able to bind to NCAM+ neuronal cells or processes (35). Kim and colleagues presented a patient with CD56+ T cell lymphoma and infiltration of the sciatic nerve (36). Other pathomechanisms exist, as Misdraji and colleagues presented four cases of CD56- lymphoma with peripheral nervous system involvement (51). Thomas and colleagues reported a patient with CD5+ and CD22+ cells in the endoneurium (which have the capacity of producing antibodies) and proposed that a neuropathy in this setting may be caused by local production of antibodies that would have easy access to antigenic sites on neuronal structures (70).

Diagnostic workup

Consultations between neurologists and internists are desirable in the care of patients with neurolymphomatosis. Some 50% of patients are only diagnosed at autopsy (15), which illustrates how difficult the diagnosis can be. Neurophysiological, laboratory, and imaging studies as well as lumbar puncture are best used in combination.

Several laboratory tests serve to identify other or coexisting causes of neuropathy. The physical exam and anatomical structures involved can influence the choice of tests. B12 folate, thyroid stimulating hormone, HgA1C, rapid plasma reagin, antinuclear antibodies, rheumatoid factor, erythrocyte sedimentation rate, c-reactive protein, and renal panel are often indicated, as well as serum and urine protein electrophoresis, for which immunofixation is much more sensitive than traditional methods. Depending on the features, myelin associated glycoprotein, GM 1 ganglioside, Yo, Hu and sulfatide antibodies as well as cryoglobulins, heavy metals, and Vitamin E levels should be assayed.

Neurophysiological studies not only define the type of nerve damage but also identify candidate nerves for biopsy. Diaz-Arrastia and colleagues found that sensorimotor axonal neuropathy was the most common finding on nerve conduction study followed by mixed axonal or demyelinating neuropathy, motor axonal neuropathy, and sensorimotor demyelinating neuropathy (15).

Partial conduction block is an early nerve conduction study abnormality in neurolymphomatosis (55).

All patients with suspected neurolymphomatosis should undergo a lumbar puncture to evaluate for leptomeningeal spread. This is typified by positive cytology. In one case, CSF cytology was normal with a traditional filter preparation, but was positive with a cytocentrifuge preparation (49). Diaz-Arrastia and colleagues studied lumbar puncture results for 30 patients with neurolymphomatosis and found that 19 had elevated protein and 21 had elevated cell counts (15). If leptomeningeal spread is a strong concern, repeat and high volume CSF analyses increase the yield because CSF cytology is frequently false negative (05).

Typical magnetic resonance imaging findings are enlarged nerves or masses that are isodense on T1-weighted images, hyperintense on T2-weighted images, and enhance with gadolinium (24; 77). In cases of inconclusive MRIs, MR neurography may be another option. MR neurography uses high resolution T1-weighted images to delineate anatomic structures and fat-suppressed T2-weighted images to detect abnormal water content in the nerves (52). In neurolymphomatosis we see the disruption of the normal fascicular morphology on T1-weighted images and hyperintensities on T2 images (52). A gallium-67 citrate scan can detect lymphomatous involvement of the brachial plexus and peripheral nerves and is used to monitor patient response to therapy (45; 33; 79). Fusion PET-CT has proven to be a powerful imaging tool for diagnosis and staging of NHL. The combined test is more accurate than either of its components and is particularly useful when a biopsy cannot be performed or the results are inconclusive or negative. Limitations include a lack of specificity because infection or inflammation can also produce a positive result. PET-CT has shown lesions along the peripheral nerves (73; 66), cranial nerves (37), and the brachial and lumbosacral plexus (08; 34; 62). Typical characteristic appearance on 18F-FDG PET/CT may take a pattern of linear or fusiform FDG-avid mass, following a neuronal path (14). PET combined with MRI and EMG proved helpful in a patient with a cervical radiculoplexopathy from a large B-cell non-Hodgkin lymphoma (60).

A nerve biopsy allows for direct visualization and characterization of the malignant cells, which may be located in the perineurium, epineurium, and endoneurium (70; 65; 15). F-18 FDG-PET/CT is a sensitive modality that can suggest the presence of malignancy and identify appropriate places for diagnostic biopsies. It is especially useful when combined with Gd-enhanced MRI (38).

There occasionally is an association with perivascular infiltrates (57; 04). Nerves involved clinically and electrophysiologically are preferable. Most commonly, the sural nerve is used; however, there are falsely negative biopsies that fail to show lymphomatous infiltrates (75; 69; 77; 56). Semithin sections provide evidence of demyelination or axonal damage (15). Cell marker studies serve to differentiate and characterize polyclonal and monoclonal infiltrates (70).

Management

The treatment is aimed at both symptoms and the underlying malignancy. The latter is the domain of the internist or oncologist. Response of non-Hodgkin lymphoma to therapy is influenced by age, histologic grade, concomitant diseases, and patient’s wishes (46). For low-grade non-Hodgkin lymphoma, radiotherapy is used for localized stage I disease, and chemotherapy is used for diffuse disease. With high-grade non-Hodgkin lymphoma the mainstay for treatment is chemotherapy, whereas radiotherapy is reserved for localized masses, compressive lesions, or lesions in the neuraxis (46). Intrathecal therapy should be considered for suspected or proven leptomeningeal involvement. Combination therapy with rituximab and chemotherapy has been shown to be superior to chemotherapy alone in other forms of non-Hodgkin lymphoma; this benefit does not appear to be the case in patients with neurolymphomatosis (19). Bendamustine, an alkylating agent, has been effective in a case of neurolymphomatosis from follicular lymphoma (74). Autologous stem cell transplantation may also be of benefit (48).

Treatment modalities for Hodgkin disease include radiotherapy, chemotherapy, or both in combination. Indications for radiotherapy are stage I disease and stage IIA disease with three or fewer areas of involvement after chemotherapy. Indications for chemotherapy are all patients with stage B disease, stage II disease with three or more areas of involvement, stage III disease, and stage IV disease (46).

Symptomatic treatment may involve ankle-foot orthoses for foot drop and splinting or elbow pads for pressure or entrapment neuropathies. If the neuropathy is severe and the patient has limited mobility, contractures must be prevented with range of motion exercises, whereas frequent turning and appropriate mattresses can prevent skin breakdown. Deconditioning can be addressed with strength and endurance exercises. Ataxia can be treated with a cane, walker, or wheelchair.

Part of the scientific evidence regarding neuropathic pain treatment comes from patients with diabetes, AIDS, cancer, trigeminal neuralgia, and shingles. Anticonvulsants (ie, gabapentin) and antidepressants in particular tricyclics have the best efficacy. Although gabapentin is often better tolerated, tricyclics have the advantage of once-daily dosing.

Tricyclic antidepressants are effective for lancinating or steady pain (64) and are usually given at hour of sleep. Use is limited by sedation, anticholinergic effects, erectile dysfunction, weight gain, and cardiac conduction abnormalities. The specific choice is often dictated by the need for nighttime sedation and the risk of daytime sedation. Doxepin and amitriptyline are the most sedative, whereas nortriptyline and desipramine are the least; their efficacy and dosage are similar. No benefit of doses above 125 mg has been documented. Initial dosing should be at 10 to 25 mg, with increases every 3 to 7 days until benefit or side effects occur. The authors obtain EKG for dose increases above 75 mg to rule out abnormal cardiac conduction. The selective serotonin reuptake inhibitors appear to be less effective that the tricyclics; this is believed to be due to the lack of noradrenalin reuptake inhibition (64). Typical doses used are fluoxetine 20 mg daily and paroxetine 20 to 40 mg daily.

Several antiepileptics are available for use including gabapentin, carbamazepine, lamotrigine, topiramate, and oxcarbazepine. Of these, gabapentin is the best tolerated, with a similar efficacy as tricyclic antidepressants. The dose of gabapentin used in neuropathic pain studies was 600 mg every 8 hours up to 3600 mg per day; carbamazepine doses ranged from 200 mg per day to 200 mg every 8 hours. Gabapentin is the authors’ preferred antiepileptic due to its generally high tolerability in the elderly as well as its wide range of effective dosage. Typically we start outpatients on 100 mg on day 1, 100 mg twice a day on day 2, 100 mg 3 times a day on day 3, 400 mg per day for the next 4 days, 400 mg twice a day for the second week, then 400 mg 3 times a day, and then slowly titrate upwards until pain is well controlled or side effects occur. Topiramate was studied in pain control starting at 25 mg per day and titrating by 25 to 50 mg per day over an 8-week period (22). Impaired cognition, drowsiness, and weight loss are not uncommon. Lamotrigine was studied starting at 25 mg per day and titrating slowly over 6 weeks to a maximum of 400 mg per day (17). Lamotrigine is associated with Stevens-Johnson syndrome and toxic epidermal necrolysis, among others.

Multiple opioid medications are available. Most physicians reserve these for severe refractory pain. Relative contraindications include a history of substance abuse, severe depression, and poor compliance. Long-acting opioids are preferred, as the steady blood levels are associated with a lower incidence of opioid “high” and constipation.

For highly localized pain, topical drugs such as lidocaine creams and transdermal patches and capsaicin cream (64) are available. Although often not providing complete pain relief, they may reduce pain significantly and, thus, reduce the required dose of other analgesics.

For patients with refractory pain, epidural morphine, clonidine, and ketamine should be considered (16; 61; 30).

References

01: Abad S, Zagdanski AM, Brechignac S, et al. Neurolymphomatosis in Waldenstrom's macroglobulinaemia. Br J Haematol 1999;106(1):100-3. PMID 10444169
02: Abuzinadah A, Almalik Y, Shabani-Rad MT, et al. Cauda equina syndrome secondary to intravascular lymphoma. Neurol Clin Pract 2012;2:158-61. PMID 23634365
03: Allison RS, Gordon DS. Reticulosis of the nervous system simulating acute infective polyneuritis. Lancet 1955;1:120-2. PMID 14392948
04: Anonymous. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 8-1995. A 75-year-old man with multiple cranial-nerve defects and weakness and pain in the extremities. N Engl J Med 1995;332(11):730-7. PMID 7854382
05: Baehring JM, Damek D, Martin EC, Betensky RA, Hochberg FH. Neurolymphomatosis. Neurooncol 2003;5:104-15. PMID 12672282
06: Balm M, Hammack J. Leptomeningeal carcinomatosis. Presenting features and prognostic factors. Arch Neurol 1996;53(7):626-32. PMID 8929170
07: Barron KD, Rowland LP, Zimmerman HM. Neuropathy with malignant tumor metastasis. J Nerv Ment Dis 1960;131:10-31. PMID 13687318
08: Bokstein F, Goor O, Shihman B, et al. Assessment of neurolymphomatosis by brachial plexus biopsy and PET/CT. Report of a case. J Neurooncol 2005;72:163-7. PMID 15925997
09: Borit A, Altrocchi P. Recurrent polyneuropathy and neurolymphomatosis. Arch Neurol 1971;24(1):40-9. PMID 5099588
10: Camerlingo M, Nemni R, Ferraro B, et al. Malignancy and sensory neuropathy of unexplained cause: a prospective study of 51 patients. Arch Neurol 1998;55(7):981-4. PMID 9678316
11: Carey M, Smith A, Townsend J. Pathologic quiz case: progressive diffuse weakness after chemotherapy for large cell lymphoma in a middle-aged woman. Lymphomatous meningitis with neurolymphomatosis. Arch Pathol Lab Med 2000;124(4):645-6. PMID 10747335
12: Chevalier X, Hermine O, Authier FJ, et al. Carpal tunnel syndrome due to T cell lymphoma. Arthritis Rheum 1995;38(11):1707-9. PMID 7488294
13: Dell PC, Guzewicz RM. Atypical peripheral neuropathies. Hand Clin 1992;8(2):275-83. PMID 1319430
14: DeVries AH, Howe BM, Spinner RJ, Broski SM. B-cell peripheral neurolymphomatosis: MRI and 18F-FDG PET/CT imaging characteristics. Skeletal Radiol 2019;48(7):1043-50. PMID 30666391
15: Diaz-Arrastia R, Younger DS, Hair L, et al. Neurolymphomatosis: a clinicopathologic syndrome re-emerges. Neurology 1992;42(6):1136-41. PMID 1340762
16: Eisenach JC, DuPen S, Dubois M, et al. Epidural clonidine analgesia for intractable cancer pain. The Epidural Clonidine Study Group. Pain 1995;61(3):391-9. PMID 7478682
17: Eisenberg E, Lurie Y, Braker C, et al. Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology 2001;57(3):505-9. PMID 11502921
18: Eusebi V, Bondi A, Cancellieri A, et al. Primary malignant lymphoma of sciatic nerve. Report of a case. Am J Surg Pathol 1990;14(9):881-5. PMID 2389819
19: Gan HK, Azad A, Cher L, Mitchell PL. Neurolymphomatosis: diagnosis, management, and outcomes in patients treated with rituximab. Neuro Oncol 2010;12(2):212-5. PMID 20150388
20: Garcin R, Gruner J, Tinel G. Sur un cas de neurolymphomatose humaine. Etude anatomo-clinique. Rev Neurol (Paris) 1953;88:81-92. PMID 13101283
21: Gherardi R, Gaulard P, Prost C, et al. T-cell lymphoma revealed by a peripheral neurolymphomatosis. A report of two cases with an immunohistologic study on lymph node and nerve biopsies. Cancer 1986;58(12):2710-6. PMID 3022911
22: Gilron I, Booher S, Rowan J, et al. Topiramate in trigeminal neuralgia: a randomized, placebo-controlled multiple crossover pilot study. Clin Neuropharmacol 2001;24(2):109-12. PMID 11307048
23: Gold J, Jimenez E, Zalusky R. Human immunodeficiency virus-related lymphoreticular malignancies and peripheral neurologic disease. A report of four cases. Cancer 1988;61(11):2318-24. PMID 3365659
24: Gordon PH, Younger DS. Neurolymphomatosis. Neurology 1996;46(4):1191-2. PMID 8780134
25: Griffin J, Thompson R, Mitchinson M, et al. Lymphomatous leptomeningitis. Am J Med 1971;51(2):200-8. PMID 4937814
26: Grisariu S, Avni B, Batchelor TT, et al. Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report. Blood 2010;115(24):5005-11. PMID 20368468
27: Harris W. Toxic polyneuritis. Brain 1922;45:415.
28: Hughes RA, Britton T, Richards M. Effects of lymphoma on the peripheral nervous system. J R Soc Med 1994;87(9):526-30. PMID 7932460
29: Ince P, Shaw P, Fawcett P, et al. Demyelinating neuropathy due to primary IgM kappa B cell lymphoma of peripheral nerve. Neurology 1987;37(7):1231-5. PMID 3037440
30: Jackson K, Ashby M, Martin P, et al. "Burst" ketamine for refractory cancer pain: an open-label audit of 39 patients. J Pain Symptom Manage 2001;22(4):834-42. PMID 11576800
31: Jellinger K, Grisold W. Unusual presentation of a primary spinal lymphoma. J Neurol Neurosurg Psychiatry 2002;72:128-9. PMID 11784846
32: Julien J, Vital C, Rivel J, et al. Primary meningeal B lymphoma presenting as a subacute ascending polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 1991;54(7):610-3. PMID 1895126
33: Kanamori M, Matsui H, Yudoh K. Solitary T-cell lymphoma of the sciatic nerve: case report. Neurosurgery 1995;36(6):1203-5. PMID 7644005
34: Kanter P, Zeidman A, Streifler J, et al. PET-CT imaging of combined brachial and lumbosacral neurolymphomatosis. Eur J Haematol 2006;74:66-9.
35: Kern WF, Spier CM, Hanneman EH, et al. Neural cell adhesion molecule-positive peripheral T-cell lymphoma: a rare variant with a propensity for unusual sites of involvement. Blood 1992;79(9):2432-7. PMID 1373974
36: Kim J, Kim YS, Lee EJ, et al. Primary CD56-positive NK/T-cell lymphoma of median nerve: a case report. J Korean Med Sci 1998;13(3):331-3. PMID 9681817
37: Kim JH, Jang JH, Koh SB. A case of neurolymphomatosis involving cranial nerves: MRI and fusion PET-CT findings. J Neurooncol 2006;80:209-10. PMID 16645712
38: Kinoshita H, Yamakado H, Kitano T, et al. Diagnostic utility of FDG-PET in neurolymphomatosis: report of five cases. J Neurol 2016;263(9):1719-26. PMID 27286845
39: Ku A, Lachmann E, Tunkel R, et al. Upper limb reflex sympathetic dystrophy associated with occult malignancy. Arch Phys Med Rehabil 1996;77(7):726-8. PMID 8670004
40: Kuntzer T, Lobrinus JA, Janzer RC, Ghika J, Bogousslavsky J. Clinicopathological and molecular biological studies in a patient with neurolymphomatosis. Muscle Nerve 2000;23(10):1604-9. PMID 11003800
41: Kuroda Y, Nakata H, Kakigi R, et al. Human neurolymphomatosis by adult T-cell leukemia. Neurology 1989;39(1):144-6. PMID 2535894
42: Lapresle J, Man HX. Signe d’Argyll Roberson dans un cas de lymphome malin avec lésions ciliaires. Rev Neurol (Paris) 1979;135(6-7):515-25. PMID 531408
43: Lee LF, Roizman B, Spear PG, Kieff ED, Burmester BR, Nazerian K. Marek's disease herpes virus: a cytomegalovirus. Proc Natl Acad Sci USA 1969;64:952-6. PMID 4313336
44: Lhermitte J, Trelles JO. Neurolymphomatose périphérique humaine. Presse Medicale 1934;42:289-92.
45: Liang R, Kay R, Maisey MN. Brachial plexus infiltration by non-Hodgkin's lymphoma. Br J Radiol 1985;58(695):1125-7. PMID 3879866
46: Mackie MJ, Ludlam CA, Haynes AP. Diseases of the blood. In: Haslett C, Chilvers E, Hunter J, Boon N, editors. Davidson’s Principles and practice of medicine. 18th ed. London: Churchill Livingstone, 1999:779-83.
47: Marek J. Multiple Nerventzündung (Polyneuritis) bei Hühnern. Dtsch Tierarztl Wochenschr 1907;15:417-21.
48: Matsue K, Hayama BY, Iwama K, et al. High frequency of neurolymphomatosis as a relapse disease of intravascular large B-cell lymphoma. Cancer 2011;117(19):4512-21. PMID 21448935
49: Mauney M, Sciotto C. Primary malignant lymphoma of the cauda equina. Am J Surg Pathol 1983;7(2):185-90. PMID 6344666
50: Meller I, Alkalay D, Mozes M, et al. Isolated metastases to peripheral nerves. Report of five cases involving the brachial plexus. Cancer 1995;76(10):1829-32. PMID 8625055
51: Misdraji J, Ino Y, Louis D, et al. Primary lymphoma of peripheral nerve: report of four cases. Am J Surg Pathol 2000;24(9):1257-65. PMID 10976700
52: Moore KR, Blumenthal DT, Smith AG, et al. Neurolymphomatosis of the lumbar plexus: high-resolution MR neurography findings. Neurology 2001;57(4):740-2. PMID 11524499
53: Odabasi Z, Parrott JH, Reddy VV, et al. Neurolymphomatosis associated with muscle and cerebral involvement caused by natural killer cell lymphoma: a case report and review of literature. J Peripher Nerv Syst 2001;6:197-203. PMID 11800041
54: Pappenheimer AM, Dunn L, Cone V. A study of fowl paralysis (neurolymphomatosis gallinarum). J Exp Med 1929;49:87-102. PMID 19869538
55: Park HJ, Shin HY, Kim SH, et al. Partial conduction block as an early nerve conduction finding in neurolymphomatosis. J Clin Neurol 2018;14(1):73-80. PMID 29629543
56: Pietrangeli A, Milella M, De Marco S, et al. Brachial plexus neuropathy as unusual onset of diffuse neurolymphomatosis. Neurol Sci 2000;21(4):241-5. PMID 11214664
57: Purohit DP, Dick DJ, Perry RH, et al. Solitary extranodal lymphoma of sciatic nerve. J Neurol Sci 1986;74(1):23-34. PMID 3723134
58: Radnai B, Takacs Nagy L. Neurolymphomatose chez l’homme. Acta Morphol 1952;2:21-33.
59: Re D, Schwenk A, Hegener P, et al. Guillain-Barre syndrome in a patient with non-Hodgkin's lymphoma. Ann Oncol 2000;11(2):217-20. PMID 10761759
60: Rosso SM, de Bruin HG, Wu KL, van den Bent MJ. Diagnosis of neurolymphomatosis with FDG PET. Neurology 2006;67:722-3. PMID 16924037
61: Samuelsson H, Malmberg F, Eriksson M, et al. Outcomes of epidural morphine treatment in cancer pain: nine years of clinical experience. J Pain Symptom Manage 1995;10(2):105-12. PMID 7537316
62: Shima K, Ishida C, Okino S, Kotani T, Higashi K, Yamada M. A linear lesion along the brachial plexus on FDG-PET in neurolymphomatosis. Intern Med 2008;47(12):1159-60. PMID 18552480
63: Shoenfeld Y, Aderka D, Sandbank U, et al. Fatal peripheral neurolymphomatosis after remission of histiocytic lymphoma. Neurology 1983;33(2):243-5. PMID 6296728
64: Sindrup SH, Jensen TS. Pharmacologic treatment of pain in polyneuropathy. Neurology 2000;55(7):915-20. PMID 11061244
65: Stack PS. Lymphomatous involvement of peripheral nerves: clinical and pathologic features. South Med J 1991;84(4):512-4. PMID 2014443
66: Strobel K, Fischer K, Hany TF, Poryazova R, Jung HH. Sciatic nerve neurolymphomatosis - extent and therapy response assessment with PET/CT. Clin Nucl Med 2007;32(8):646-8. PMID 17667443
67: Stuart JE, Smith AC. Plasmacytoma of the superficial radial nerve. J Hand Surg [Am] 2001;26(4):776-80. PMID 11466657
68: Suzuki M, Watanabe T, Mogi G. Primary non-Hodgkin's lymphoma of brachial plexus. Auris Nasus Larynx 1999;26(3):337-42. PMID 10419043
69: Swarnkar A, Fukui M, Fink D, et al. MR imaging of brachial plexopathy in neurolymphomatosis. AJR 1997;169(4):1189-90. PMID 9308489
70: Thomas FP, Vallejos U, Foitl D, et al. B-cell small lymphocytic lymphoma and chronic lymphocytic leukemia with peripheral neurolymphomatosis: two cases with neuropathologic findings and lymphocyte marker analysis. Acta Neuropathol 1990;80:197-202. PMID 2167605
71: Toner GC, Holmes R, Sinclair R, et al. Central nervous system lymphoma: primary lumbar nerve root infiltration. Acta Haematol 1989;81(1):44-7. PMID 2494834
72: Trelles JO, Trelles L. La neurolymphomatose périphérique. Rev Neurol (Paris) 1983;139(12):703-14. PMID 6320325
73: Trojan A, Jermann M, Taverna C, et al. Fusion PET-CT imaging of neurolymphomatosis. Ann Oncol 2002;13:802-5. PMID 12075752
74: Umeda M, Kondo T, Nishikori M, et al. A case of neurolymphomatosis caused by follicular lymphoma successfully treated with bendamustine. Clin Case Rep 2015;4(1):23-5. PMID 26783429
75: Vallat JM, De Mascarel HA, Bordessoule D, et al. Non-Hodgkin malignant lymphomas and peripheral neuropathies-13 cases. Brain 1995;118:1233-45. PMID 7496783
76: Van den Bent MJ, de Bruin HG, Beun GD, et al. Neurolymphomatosis of the median nerve. Neurology 1995;45(7):1403-5. PMID 7617204
77: Van den Bent MJ, de Bruin HG, Bos GM, et al. Negative sural nerve biopsy in neurolymphomatosis. J Neurol 1999;246(12):1159-63. PMID 10653308
78: Vital C, Vital A, Broustet A, et al. Neurolymphomatosis. Neurology 1993;43(8):1627-8. PMID 8351033
79: Walk D, Handelsman A, Beckmann E, et al. Mononeuropathy multiplex due to infiltration of lymphoma in hematologic remission. Muscle Nerve 1998;21(6):823-6. PMID 9585343
80: Wulff E, Simpson D. Peripheral neurolymphomatosis associated with acquired immunodeficiency syndrome (AIDS)-related Burkitt's lymphoma. Muscle Nerve 2000;23(11):1764-6. PMID 11054758
81: Zimmerman HM. Malignant lymphomas of the nervous system. Acta Neuropathol Suppl (Berl) 1975;(Suppl 6):69-74. PMID 1098376

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Florian P Thomas MD MA PhD MS

Dr. Thomas of Hackensack Meridian School of Medicine has no relevant financial relationships to disclose.
See Profile
Niranjan N Singh MD

Dr. Singh of the University of Missouri-Columbia received honorariums from AbbVie for speaking engagements.
See Profile

Editor

Louis H Weimer MD

Dr. Weimer of Columbia University has no relevant financial relationships to disclose.
See Profile

Former Authors

Alan L Diamond DO

Patient Profile

Age range of presentation: 6 to 65+ years
Sex preponderance: male 3: female 2
Heredity: none
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-9: Malignant neoplasm with polyneuropathy: 199.1

Malignant lymphoma: 200.1

Malignant undifferentiated lymphoma: 200.2

Hodgkin lymphoma: 201.9

Non-Hodgkin lymphoma: 202.8

Other lymphoma, multiple sites: 202.88
ICD-10: Malignant neoplasm without specification of site: C80

Malignant lymphoma: C85.9

Hodgkin lymphoma: C81.9

Non-Hodgkin's lymphoma, unspecified type: C85.9

Other and unspecified T-cell lymphomas: C84.5

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Neurolymphomatosis

Associated Disorders

Hodgkin disease
Non-Hodgkin disease

Differential Diagnosis

lymphoma
diabetes mellitus
neurotoxic drugs
substance abuse
nutritional deficiency
- hematologic conditions
- neoplastic conditions
- paraneoplastic conditions
- vasculitides
- connective tissue disorders
- porphyria
- infectious polyneuritis
- nerve compression
- schwannoma
- neurosarcoidosis
- Lyme disease
- Whipple disease
- amyloidosis
- new-onset dementia
- cranial neuropathies
- early severe neuropathic pain
- asymmetric features
- acute demyelinating polyneuropathy
- progressive neurolymphomatosis

Also Relevant

Primary CNS lymphoma
Peripheral neuropathies: supportive measures and rehabilitation
Peripheral neuropathies: treatment with neurotrophic factors

Neurolymphomatosis …

Neurolymphomatosis

Introduction

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Differential diagnosis

Diagnostic workup

Management

Media

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

NF2-related schwannomatosis

Familial dysautonomia

Tumors of the skull base

Peripheral nerve complications of HIV-1 infection

Neuropathies associated with cytomegalovirus infection

Disulfiram neuropathy

Mercury neuropathy

Clinical evaluation of peripheral neuropathies

Neurolymphomatosis

Introduction

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Differential diagnosis

Diagnostic workup

Management

Media

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

NF2-related schwannomatosis

Familial dysautonomia

Tumors of the skull base

Peripheral nerve complications of HIV-1 infection

Neuropathies associated with cytomegalovirus infection

Disulfiram neuropathy

Mercury neuropathy

Clinical evaluation of peripheral neuropathies

This is an article preview.
Start a Free Account
to access the full version.